广生堂 (300436)
Fujian Cosunter Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameFujian Cosunter Pharmaceutical Co., Ltd.
Listing Date2015-04-22
Issue Price21.47RMB
Registered Capital15926.710k RMB
Legal RepresentativeLi Guoping
Registered AddressBuilding 1-7, Fuyuan Industrial Park, Zherong County, Ningde City, Fujian Province
IndustryChemical Pharmaceuticals
Main BusinessEngaged in the research and development, production, and sales of nucleoside anti-hepatitis B virus drugs.
Company ProfileCosunter is a high-tech enterprise focused on the field of liver disease treatment drugs. It possesses four preferred nucleoside/nucleotide anti-hepatitis B virus drugs: Tenofovir, Entecavir, Lamivudine, and Adefovir Dipivoxil. To date, the company has obtained over fifty national patents in the field of liver drugs. On April 22, 2015, the company was successfully listed on the Shenzhen Stock Exchange, stock code 300436.
The national Class I new drug Agan Ding (Adefovir Dipivoxil), which took five years to develop and holds five patents, was awarded the "First Prize of Fujian Science and Technology Invention Award" and the "Special Prize of Fujian Patent Award". He Gan Ding (Lamivudine) was selected for the "National 12th Five-Year Plan Major Science and Technology Project" and the "Major New Drug Innovation Program". The capsule formulation of Entecavir — En Gan Ding, launched in 2012, features advanced technology and stable quality, and has been selected as the clinical research drug for several national 12th Five-Year Plan projects. In May 2017, Cosunter obtained approval for the hepatitis B indication of the new anti-hepatitis B virus drug Tenofovir. "Fu Gan Ding" — Tenofovir Disoproxil Fumarate Capsules was launched and selected for the 2018 implementation plan of the national "Major New Drug Innovation Program" science and technology major project. Cosunter continues to improve its coverage of cutting-edge products in China's anti-hepatitis B virus drug field.
Stock Details
1. Key Indicators
- Total Shares(W): 15926.70
- Circulating A-Shares(W): 13671.98
- Earnings Per Share(RMB): -0.7006
- Net Assets Per Share(RMB): 2.4050
- Operating Revenue(W RMB): 31583.81
- Total Profit(W RMB): -10715.63
- Net Profit Attributable to Parent(W RMB): -11158.44
- Net Profit Growth Rate(%): -57.96
- Weighted Return on Equity(%): -36.6600
- Operating Cash Flow Per Share(RMB): -0.2830
- Undistributed Profit Per Share(RMB): -3.5349
- Capital Reserve Per Share(RMB): 4.6611
2. Main Business
The main business covers:
- Providing scientific solutions for human liver health
3. Company Basic Information
- Company Name: Fujian Cosunter Pharmaceutical Co., Ltd.
- Listing Date: 2015-04-22
- Industry: Pharmaceutical Manufacturing
- Address: Building 16, Phase II Innovation Park, Haixi High-tech Industrial Park, No.7 Wulongjiang Middle Avenue, Fuzhou High-tech Zone, Minhou County, Fuzhou City, Fujian Province
- Website: www.cosunter.com
- Company Profile: The company was established by converting Guang Sheng Tang Co., Ltd. into a joint-stock company based on its audited net assets of RMB 44,427,973.90 as of July 31, 2011, at a ratio of 1:0.788, resulting in 35 million shares. The promoters contributed the net assets corresponding to their respective equity interests in Guang Sheng Tang Co., Ltd. This capital contribution was verified by Fujian Huaxing Certified Public Accountants Co., Ltd., which issued the Min Huaxing Suo (2011) Yan Zi H-011 “Capital Verification Report.” On September 30, 2011, the company completed the industrial and commercial change registration procedures at the Ningde City Administration for Industry and Commerce in Fujian Province, with the enterprise legal person registration number: 350926100003095 and registered capital of RMB 35 million.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Fujian Aohua Group Co., Ltd. | Corporate Legal Person | 2706.87 | 19.80 |
| 2 | Fujian Pingtan Aotai Technology Investment Center (Limited Partnership) | Corporate Legal Person | 802.50 | 5.87 |
| 3 | Zhangzhou Zhanxin Venture Capital Fund Management Co., Ltd. - Zhangzhou Yuanshan Great Health Industry Investment Fund Partnership (Limited Partnership) | Asset Management Plan | 800.00 | 5.85 |
| 4 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 174.63 | 1.28 |
| 5 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 70.82 | 0.52 |
| 6 | Tongtai Great Health Theme Hybrid Securities Investment Fund Class A | Fund | 4.06 | 0.03 |
| 7 | Jinxin Value Select Flexible Allocation Hybrid Fund Class A | Fund | 1.10 | 0.01 |
5. Concept Sectors
- West Coast of the Taiwan Strait
- Gene Concept
- Generic Drugs
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- High Price-to-Book Ratio
- Loss-Making Stocks
- Consecutive Losses
- Equity Transfer
- Increasing Shareholder Count
- ChiNext 300
- ChiNext Pharmaceuticals
- ChiNext Small Cap
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information